NovaBridge Biosciences (NBP) Liabilities from Discontinued Operations (2023)
NovaBridge Biosciences (NBP) reported Liabilities from Discontinued Operations of 50975000.0 for Q4 2023.
NovaBridge Biosciences (NBP) Liabilities from Discontinued Operations (2023) Analysis & Trends
NovaBridge Biosciences (NBP) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 50975000.0 in Q4 2023.
- Liabilities from Discontinued Operations for Q4 2023 came in at 50975000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 50975000.0 (changed N/A YoY), and the FY2023 annual result was 50975000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations steadied at 50975000.0 in Q4 2023 per NBP's latest filing.
- Over five years, Liabilities from Discontinued Operations peaked at 50975000.0 in Q4 2023 and troughed at 50975000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -50.98 Mn |
| Dec 31, 2023 | -50.98 Mn |